Cerdulatinib for treating hematological cancers
Disclosed herein are methods and uses of cerdulatinib for treating diseases or conditions, including hematological cancers, and combinations of cerdulatinib for treating such diseases or conditions.
1. A method for treating a hematologic cancer in a patient in need thereof, comprising administering to the patient an effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, and an effective amount of rituximab, or a pharmaceutically acceptable salt thereof, wherein cerdulatinib and rituximab are present in a molar ratio of about 2:1 to about 1:5.
2. The method of claim 1 , wherein the hematologic cancer is non-Hodgkin's lymphoma (NHL).
3. The method of claim 1 , wherein the hematologic cancer is selected from Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), transformed Follicular Lymphoma (tFL), Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma, Mucosa-Associated Lymphoid Tissue (MALT), and Waldenstrom Macroglobluinemia (WM).
4. The method of claim 3 , wherein the hematologic cancer is FL.
5. The method of claim 3 , wherein the hematologic cancer is tFL.
6. The method of claim 3 , wherein the hematologic cancer is SLL.
7. The method of claim 1 , wherein cerdulatinib and rituximab are administered concurrently or sequentially.
8. The method of claim 1 , wherein the patient has a drug resistant and/or relapsed form of the hematologic cancer.
9. The method of claim 8 , wherein the patient has a mutation linked to relapse and/or a resistance to another drug for treating a hematologic cancer.
10. The method of claim 8 , wherein the patient has a resistance to a chemotherapeutic agent.
11. The method of claim 1 , wherein the patient was previously administered a drug selected from an alkylating agent, an anti-CD20 antibody, a BCL-2 inhibitor, a BTK inhibitor, a P13Kδ inhibitor, a platinum-based drug, an antimetabolite, an anthracycline, a BCR pathway inhibitor, and another chemotherapeutic agent used for treating a hematologic cancer.
12. The method of claim 1 , wherein the patient was previously administered a drug selected from venetoclax, rituximab, ibrutinib, idelalisib, and fludarabine.
13. The method of claim 1 , wherein the patient expresses a Bcl-2 protein.
14. The method of claim 1 , wherein the patient expresses a Bim protein.
15. The method of claim 1 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 25 mg to about 120 mg administered daily.
16. The method of claim 1 , wherein the patient has a CD79B mutation, has a PLCγ2 mutation, or does not have a IKB deletion, wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 25 mg to about 120 mg administered daily.
17. The method of claim 1 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 60 mg in two administrations of about 30 mg.
18. The method of claim 1 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 50 mg in two administrations of about 25 mg.
19. The method of claim 1 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 40 mg in two administrations of about 20 mg.
20. The method of claim 1 , wherein the effective amount of cerdulatinib, or a pharmaceutically acceptable salt thereof, is about 30 mg in two administrations of about 15 mg.